ReviewCurrent oncology reports2010
Biology and therapy of neoplastic meningitis.
Review in Current oncology reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Review
- Review
- Radiotherapy for Leptomeningeal Carcinomatosis in Breast Cancer Patients: A Narrative Review.Cancers · 2022Review
- Characteristics of Patients with Meningeal Carcinomatosis Combined with Myelopathy.Neuropsychiatric disease and treatment · 2022Article
- Neoplastic meningitis due to colorectal cancer.Clinical journal of gastroenterology · 2020Article
- Breast leptomeningeal disease: a review of current practices and updates on management.Breast cancer research and treatment · 2019Review
- CDK 4/6 inhibitors and stereotactic radiation in the management of hormone receptor positive breast cancer brain metastases.Journal of neuro-oncology · 2019Article
- Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments.Therapeutic advances in neurological disorders · 2018Review
- Diagnostic Value of CYFRA 21-1 in the Cerebrospinal Fluid for Leptomeningeal Metastasis.Disease markers · 2017Article
- Meningeal carcinomatosis underdiagnosis and overestimation: incidence in a large consecutive and unselected population of breast cancer patients.BMC cancer · 2015Article
- Physiology of the intrathecal bolus: the leptomeningeal route for macromolecule and particle delivery to CNS.Molecular pharmaceutics · 2013Review
- How to recognize and treat neoplastic meningitis.Journal of the advanced practitioner in oncology · 2013Review
- Neoplastic meningitis from solid tumors: a prospective clinical study in lombardia and a literature review on therapeutic approaches.Journal of drug delivery · 2013Article
- Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases.Oncotarget · 2011Article
- Detection of cancer cells in the cerebrospinal fluid: current methods and future directions.Fluids and barriers of the CNS · 2011Article
- Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches.The oncologist · 2011Review
- Intracranial Leptomeningeal Carcinomatosis in Three Cases from Breast Cancer Demonstrated on F-18 Fluorodeoxyglucose Positron Emission Tomography/Computerized Tomography.Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, IndiaArticle
- CSF Involvement by Nonhematolymphoid Malignancies: A Descriptive Study with Emphasis on Cytomorphological Clues.Journal of cytologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoplastic meningitis (NM) occurs in 5% to 8% of cancer patients, commonly as an end-stage process in previously metastatic disease. As newer therapeutics extend patient survival by maintaining long-term control of systemic malignancies, the incidence of NM is likely to rise. This can be expected both because of a change in the natural history of the underlying disease and the generally poor penetrance of many newer anticancer drugs into the central nervous system, thereby creating a sanctuary site for malignant cells. Currently available treatments have provided limited benefit in overall survival in NM, although long-term survival does occur. Because of the morbidity occasionally associated with treatment, prognostic indicators are being analyzed to identify patients who may benefit from systemic and/or intrathecal therapy before making the decision to initiate treatment. Additionally, because of the relative insensitivity of traditional cerebrospinal fluid analysis, new markers of NM are being investigated. This endeavor is being aided by ongoing research into the underlying biology of the metastatic process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.